North America Eliquis Market Size & Outlook, 2025-2033
Related Markets
North America eliquis market highlights
- The North America eliquis market generated a revenue of USD 6,739.5 million in 2024.
- The market is expected to grow at a CAGR of -2% from 2025 to 2033.
- In terms of segment, atrial fibrillation (af) was the largest revenue generating indication in 2024.
- Atrial Fibrillation (AF) is the most lucrative indication segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2025 to 2033.
North America data book summary
| Market revenue in 2024 | USD 6,739.5 million |
| Market revenue in 2033 | USD 6,259.1 million |
| Growth rate | -2% (CAGR from 2025 to 2033) |
| Largest segment | Atrial fibrillation (af) |
| Fastest growing segment | Atrial Fibrillation (AF) |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Atrial Fibrillation (AF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Post-Operative VTE Prophylaxis (at-risk cases) |
Other key industry trends
- In terms of revenue, North America region accounted for 32.6% of the global eliquis market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 5,019.3 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Eliquis Market Scope
Eliquis Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Mylan N.V. | View profile | - | - | - |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| GSK PLC ADR | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
North America eliquis market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to eliquis market will help companies and investors design strategic landscapes.
Atrial fibrillation (af) was the largest segment with a revenue share of 66.89% in 2024. Horizon Databook has segmented the North America eliquis market based on atrial fibrillation (af), deep vein thrombosis (dvt), pulmonary embolism (pe), post-operative vte prophylaxis (at-risk cases) covering the revenue growth of each sub-segment from 2021 to 2033.
North America Eliquis (apixaban) market held the largest share of 32.56% in 2024, due to the high prevalence of atrial fibrillation and widespread clinical adoption of DOACs: advanced diagnostic capabilities and robust healthcare infrastructure support early identification and long-term management of thromboembolic disorders.
Eliquis benefits from favorable positioning in treatment guidelines and strong trust among cardiologists. Ongoing clinical trials and post-marketing surveillance continue to reinforce its safety and efficacy.
High prescription rates are also driven by growing awareness among aging populations. Strategic partnerships and effective distribution channels further strengthen its market hold across the region.
Reasons to subscribe to North America eliquis market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America eliquis market databook
-
Our clientele includes a mix of eliquis market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America eliquis market , including forecasts for subscribers. This continent databook contains high-level insights into North America eliquis market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
North America eliquis market size, by country, 2021-2033 (US$M)
North America Eliquis Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
